Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
TScan Therapeutics Inc (TCRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.21+11.11%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TCRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Initiate Phase 1 study of TSC-102-A01 and TSC-102-A03 in H2 2026 | A primary condition in TScan Therapeutics Inc's published investment case. The stated target is Phase 1 study start in H2 2026. | Under Pressure | Phase 1 studies not initiated by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making clinical-stage biotechnology company, not a proven earnings compounder. Its multi-year view is in a watch state: management has set new development milestones, but recent restructuring and funding constraints make execution uncertain.
The valuation evidence is mixed and low confidence: one measure points to TCRX being cheap versus peers, while another indicates a 41% premium. The expectations gap is close to neutral, so the snapshot does not show a clear market expectation for a major change in performance.
Near term, fundamentals face pressure from paused enrollment in the Phase 3 TSC-101 study due to capital constraints, a CEO transition, and an officer change. TSC-102-A01 and TSC-102-A03 remain planned for Phase 1 studies in the second half of 2026, while two in vivo-engineered TCR-T candidates are in IND-enabling studies, with Phase 1 planned for Q4 2027.
The multi-year thesis depends on whether TCRX can secure funding or partnerships, resume TSC-101 enrollment, and meet its clinical milestones after the strategic pivot. Near-term risks include a guidance cut and weaker jobs data; stronger results and guidance from large Healthcare companies could support sector momentum, but would not resolve TCRX’s company-specific funding and execution risks.
For the next one to three years, TCRX remains a high-risk development story with a changed pipeline and meaningful funding and leadership uncertainty. Its long-term thesis depends on translating planned programs into clinical progress while managing these constraints. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| TScan is advancing its TSC-101 pivotal trial as planned in Q2 2026. |
| Under Pressure |
| Trial launch delayed beyond Q2 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth near or above -10% in FY26 | A primary condition in TScan Therapeutics Inc's published investment case. The stated target is Revenue decline no worse than -10% in FY26. | Broken | Revenue decline worse than -10% in FY26 | Revenue growth: -65.83% FY2026-Q2; GAAP. Published target: Revenue decline no worse than -10% in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-65.83225 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.97 → $-0.60 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-07-25 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-07-26 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-07-27 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-07-28 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-07-29 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-07-30 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-07-31 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-08-01 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-02 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-08-03 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-04 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-08-05 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-06 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-08 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-09 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-08-10 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-12 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-08-13 | $-0.89 | $7,807,060 | 4 / 5 |
| 2026-08-14 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-15 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-16 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-17 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-18 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-19 | $-0.97 | $7,807,063 | 4 / 4 |
| 2026-08-20 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-21 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-22 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-23 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-24 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-25 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-26 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-27 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-28 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-29 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-30 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-08-31 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-09-01 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-09-02 | $-1.01 | $6,511,463 | 4 / 4 |
| 2026-09-03 | $-0.94 | $6,511,463 | 4 / 4 |
| 2026-09-04 | $-0.83 | $4,711,463 | 4 / 4 |
| 2026-09-05 | $-0.83 | $4,711,463 | 4 / 4 |
| 2026-09-06 | $-0.83 | $4,711,463 | 4 / 4 |
| 2026-09-07 | $-0.83 | $4,711,463 | 4 / 4 |
| 2026-09-08 | $-0.83 | $4,711,463 | 4 / 4 |
| 2026-09-09 | $-0.71 | $3,276,663 | 4 / 4 |
| 2026-09-10 | $-0.71 | $3,276,663 | 4 / 4 |
| 2026-09-11 | $-0.71 | $3,276,663 | 4 / 4 |
| 2026-09-12 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-13 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-14 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-15 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-16 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-17 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-18 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-19 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-20 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-21 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-22 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-23 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-24 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-25 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-26 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-27 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-28 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-29 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-09-30 | $-0.71 | $3,276,663 | 4 / 3 |
| 2026-10-01 | $-0.71 | $3,276,663 | 3 / 3 |
| 2026-10-02 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-03 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-04 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-05 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-06 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-07 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-08 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-09 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-10 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-11 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-12 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-13 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-14 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-15 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-16 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-17 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-18 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-19 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-20 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-21 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-22 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-23 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-24 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-25 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-26 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-27 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-28 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-29 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-30 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-10-31 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-11-01 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-11-02 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-11-03 | $-0.60 | $1,250,000 | 3 / 3 |
| 2026-11-04 | $-0.60 | $1,250,000 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.